Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Limited (NASDAQ: IXHL) is a clinical-stage biotechnology company developing pharmaceutical products and therapies for conditions with significant unmet medical needs. The company’s research focuses on cannabinoid- and psychedelic-assisted treatments, with programs addressing sleep-disordered breathing, pain, inflammation, mental health and other complex disorders.

One of Incannex’s principal programs is IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea. The company has also pursued cannabinoid-based candidates for inflammatory and fibrotic diseases, pain conditions and traumatic brain injury, as well as psychedelic-assisted therapies for psychiatric disorders such as generalized anxiety disorder. These products remain investigational and are subject to clinical and regulatory review.

Founded in Australia, Incannex has conducted research and clinical development activities in Australia and the United States. The company’s securities trade on the Nasdaq Capital Market under the symbol IXHL, and it has historically been led by Managing Director and Chief Executive Officer Joel Latham. Incannex’s development strategy is centered on advancing its drug candidates through clinical trials and, where appropriate, seeking regulatory approval and commercialization partnerships.

Key Stats

• Today's Range: $3.37 to $3.47
• 50-Day Range: $2.91 to $3.80
• 52-Week Range: $2.49 to $19.71
• Volume: 60,027 shs
• Average Volume: 90,590 shs
• Market Capitalization: $40.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Hold

Incannex Healthcare Stock Analysis - MarketRank™

Incannex Healthcare scored higher than 38% of companies evaluated by MarketBeat, and ranked 785th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Incannex Healthcare has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Incannex Healthcare has a consensus price target of $18.00, representing about 429.4% upside from its current price of $3.40.

Amount of Analyst Coverage

Incannex Healthcare has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Incannex Healthcare are expected to grow in the coming year, from ($1.38) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incannex Healthcare is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incannex Healthcare is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Incannex Healthcare has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.07% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 10.01, which indicates bearish sentiment.

Change versus previous month

Short interest in Incannex Healthcare has recently decreased by 2.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incannex Healthcare does not currently pay a dividend.

Dividend Growth

Incannex Healthcare does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Incannex Healthcare has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Incannex Healthcare this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for IXHL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

5 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.33% of the stock of Incannex Healthcare is held by insiders.

Percentage Held by Institutions

0.43% of the stock of Incannex Healthcare is held by institutions.

Company Calendar

• Last Earnings: 2/13/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 9/25/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IXHL
• CIK: 1873875
• Web: www.incannex.com.au
• Phone: +61409840786
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Incannex Healthcare: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +429.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.01%
• Return on Assets: -76.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 41.56
• Quick Ratio: 41.56

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 452.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 11,970,000
• Free Float: 11,806,000
• Market Cap: $40.70 million
• Optionable: Not Optionable
• Beta: 6.97